Category: Research

Categories
LICs LICs

Future Generation Investment Company Ltd

Future Generation provides high diversification by investing in about 20 funds managed by diverse Australian fund managers who work for free.

At least 10 holdings are likely to be represented in each of those portfolios. As a result, there are several underlying shares that provide adequate diversification.

Future Generation has a pretty strong dividend yield of 6.6 percent when grossed up. Currently, Future Generation provides fully frank divided yield is 3.8% due to Covid -19 Pandemic  Company decreases there dividend yield.

Current performance of Future Generation Portfolio for last 6 months is 12.8% and there outperformance for 6 month is 0.2%. S&P/ASX All Ordinaries Accummulation Index for past 3 years it is 10.3%.

(Source: The Motley Fool)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
LICs LICs

LICs that are sold for less than their true value

The LIC may or may not be completely transparent when it comes to revealing its holdings or NTA [net tangible assets]/performance numbers, and the costs are substantially higher — moreover they usually earn a bonus if they outperform.

LIC share prices, like that of every other publicly traded company, fluctuate based on supply and demand. This means that while the fund may have $1 in assets per share, the stock may be trading for 80 percents… or $1.20.

A large fish may buy out LIC, which is trading at a significant discount to the NTA, and liquidate it for a profit.

LICs can occasionally provide good discounts.

LIC managers tend to get upset when their fund gravy train gets taken away from them

The LIC gets smacked sometimes, especially during periods of acute lack of confidence, while the assets it holds bounce swiftly, thus buying the LIC at a discount is like going back in time and buying those equities before the rally.

(Source: The Motley Fool)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
LICs LICs

NCC With High Dividend Yields of Over 7%

Experience Co Ltd (ASX: EXP), Saunders International Ltd (ASX: SND), and Contango Asset Management Ltd are some of its current investments (ASX: CGA).

COVID-19’s effects on industrial small cap stocks have made things difficult in 2020. Despite this, since its debut in February 2013, Naos Emerging Opportunities has generated an average annual return of 10.1 percent (after expenses but before fees). The same rate is been marked in 2021 also.

The LIC has increased its dividend every year since FY13 due to which the high dividend yield appears to be safe for the next few coming years. It has a profit reserve of 32.7 cents per share, or nearly four years’ worth of dividends at the current rate.

Its current post tax NTA is $1.18 and NCC INVESTMENT PORTFOLIO PERFORMANCE SINCE INCEPTION is 13.44% marked in June 30, 2021. Even with the strong FY21 performance it is also worth adding that a number of the NCC core investments didn’t perform as expected and, in some cases, actually detracted from overall performance.

 (Source: fool.com.au)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
LICs LICs

The War of WAM on ASX! Wilson’s New LIC Hits the Share Market

The founder of WAM in charge of WAM Strategic Value is Geoff Wilson, assures investors in WAM Strategic Value’s ASX WAR prospectus that the company will focus on “finding and investing in $1 of assets for 80 cents.

The LIC intends to accomplish this by grabbing the opportunity of market mispricing like securities trading at discounts to assets or NTA (net tangible assets), corporate transactions, and dividend yield arbitrages with franking credit benefits.

WAM Strategic Value will largely be in the business of purchasing assets from other LICs and Listed Investment Trusts (LITs) for less than their true value. After all, with its $200 million+ funding, it’s likely invested in quite a bit so far. Back then, their units were trading at a 12.2 percent discount to their NTA value.

(Source: msn.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
IPO Watch

Industrial SPAC Kensington Capital Acquisition V files for a $260 million IPO

Each warrant authorises the holder to purchase one share of the Company’s Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. 

The offering was expected to close on June 30, 2020, subject to customary closing conditions.

Kensington Capital Acquisition V, a blank check business run by Kensington Capital’s founder and focused on industrials, filed with the SEC on Monday to raise up to $260 million.

The business, situated in Westbury, New York, hopes to generate $260 million by selling 26 million units at $10 each. One share of common stock and one-fifth of a warrant, exercisable at $11.50, are included in each unit. Kensington Capital Acquisition V would have a market value of $325 million at the anticipated deal size.

Company Profile

Kensington Capital Acquisition V was founded in 2021 and plans to list on the NYSE under the symbol KCGI.U. The company filed confidentially on June 10, 2021. UBS Investment Bank is the sole bookrunner on the deal. Kensington Capital Acquisition Corp. II operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

(Source: NASDAQ.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
ipo IPO Watch

IMV Prices 14.3 M Units of Public Offering at $1.75/Unit

One common share and three-quarters of a common share purchase warrant are included in each Unit. Each Warrant authorises the holder to purchase one common share at a price of US$2.10 per common share for a period of 60 months following the closure of the Offering, subject to adjustment in certain conditions.

The Offering is scheduled to close on or around July 20, 2021, with the common shares underlying the Units and Warrants proposed for listing on the TSX and Nasdaq.

The Corporation plans to use the net proceeds of the Offering to continue clinical development of maveropepimut-S (DPX-Survivac) in DLBCL, breast cancer, ovarian cancer, bladder cancer, and microsatellite instability high (MSI-H), as well as to begin clinical development of a new product, DPX-SurMAGE, in bladder cancer, continuing to develop its patented drug delivery technology (DPX), as well as for other corporate reasons.

Company Profile

Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.

(Source:  RTT News)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
IPO Watch

The Fresh Market Files for an IPO Price estimated at $250 Million

In March 2011, the company went public, raising $290 million, before being acquired and taken private by Apollo Global Management for $1.4 billion in 2016.

On March 12, 2021, The Fresh Market filed a confidential filing. The deal’s joint book runners are Credit Suisse, BofA Securities, Barclays, Deutsche Bank, RBC Capital Markets, BMO Capital Markets, Guggenheim Securities, and Apollo Global Securities. There were no pricing details provided.

Company Profile

The Fresh Market offers high-quality, fresh goods and hard-to-find items in a small, intimate store with great cleanliness and high-touch guest care. It is an Apollo-backed fresh food supermarket with over 150 locations in 22 states.

(Source: NASDAQ.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
IPO Watch

EVmo a ridesharing rental service to raise IPO to $12 Million

The Beverly Hills, California-based company was created in 2016 and has revenue of $8 million for the year ending March 31, 2021. It intends to trade under the symbol “EVMO” on the NASDAQ. The deal’s sole book runner is Think Equity. There were no pricing details provided.

Company Profile

EVmo, Inc. connects rideshare drivers in need of a suitable car with rideshare firms that rely on attracting and retaining drivers. It operates primarily in Rideshare Car Rentals and Distinct Cars, two wholly-owned subsidiaries. Rideshare has an online reservation system. Customers who are drivers in the ridesharing and delivery gig industries can rent a fleet of passenger vehicles and transit vans for usage in the last-mile logistical space from Distinct Cars, which also provides them with insurance coverage and issues them insurance cards in their own names.

(Source: NASDAQ)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
IPO Watch

B2B software SPAC Bannix Acquisition cuts deal size by 50% ahead of $50 million IPO

One share of common stock, one right to earn one-tenth of a share upon completion of an initial business combination, and one warrant, exercisable at $11.50, are included in each unit.

Bannix Acquisition will raise -50% less money under the new deal size than it had planned.

Company Profile

Bannix Acquisition Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We intend to focus on B2B enterprise software companies, particularly those operating in the Customer Engagement space within the telecom, retail and financial services sectors. We will target businesses located in North America and Western Europe, ideally those with a recurring revenue model and an overall transaction value of at least $400 million.

(Source: NASDAQ.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
ipo IPO Watch

Terms out for Clarity’s $358 million IPO

Oncology imaging technologies and medicines are the focus of Clarity. It’s working on Targeted Copper Theranostic (TCT) products, which allow copper to be utilised in the diagnosis and treatment of malignancies like prostate and breast cancer, as well as uncommon and orphan diseases like neuroblastoma, which arises from immature nerve cells in children.

It will undoubtedly be compared to Telix, the only other publicly traded radiopharmaceutical business, which has gained 38.4% year to date and has a market capitalization of $1.6 billion.

Clarity is chaired by Alan Taylor, a former Inteq consultant who handled a number of Australian listings, and is run by Colin Biggin, a former Algeta executive. Major supporters such as Australian Unity and Sydney-based investment manager Firetrail Investments joined KKR-backed GenesisCare in a $25 million pre-IPO funding round last year.

Company Profile

Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR Technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

(Source: AFR News)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.